Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13 mai 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09 mai 2024 16h05 HE
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
30 avr. 2024 08h05 HE
|
Senti Biosciences, Inc.
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
14 mars 2023 16h35 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders
01 mars 2023 06h00 HE
|
Yasheng Group
San Jose, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders; Begins Raising Capital for our Subsidiary, Jove Pharmaceutics...
Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development
24 févr. 2023 03h30 HE
|
Yasheng Group
San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February 24, 2023) - Yasheng Group, (OTC:...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2020 16h07 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum to Participate in Two Upcoming Virtual Conferences
28 sept. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
02 sept. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 août 2020 16h07 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...